Pregnancy, parturition and preeclampsia in women of African ancestry

Annettee Nakimuli, MBChB, MMed (Obs&Gyn); Olympe Chazara, PhD; Josaphat Byamugisha, MBChB, MMed (Obs&Gyn), PhD; Alison M. Elliott, MA, MBBS, MD, DTM&H, FRCP; Pontiano Kaleebu, MD, PhD; Florence Mirembe, MBChB, MMed (Obs&Gyn), PhD; Ashley Moffett, MA, MB, BChir, MD, MRCP, MRCPath

More than 90% of maternal deaths worldwide occur in sub-Saharan Africa (SSA) and south Asia. These high maternal and associated neonatal mortality rates persist despite considerable efforts from the World Health Organization, governments, development partners, and others. The majority of these deaths are related to pregnancy complications that are inadequately managed because of a lack of access to emergency health care. The maternal mortality ratios (MMRs) of Sweden, the United Kingdom, and the United States are 4, 12, and 21, respectively, whereas those of Chad, Nigeria, and Congo are 1100, 630, and 540 per 100,000 live births, respectively. In SSA, the major direct causes of maternal mortality are hemorrhage, preeclampsia/eclampsia, obstructed labor, and sepsis. Infections, preterm birth, birth asphyxia, stillbirths, and small-for-gestational-age infants are the leading causes of perinatal mortality.

These observations are representative of our own institution, Mulago Hospital in Kampala (Uganda) in which the MMR has remained high at 438 per 100,000 live births, even though there has been an increase in skilled birth attendance (58%) and very good attendance rate (95%) at antenatal clinics.

Mulago Hospital is the busiest maternity hospital in SSA, serving as a tertiary referral center for Uganda. Details of deliveries and maternal deaths are shown in Table 1. Even with the lack of good medical records that is characteristic of much of SSA, our experience in Mulago Hospital is that causes of maternal deaths are similar to the rest of SSA, with hemorrhage, preeclampsia/eclampsia, and sepsis occurring very commonly. The large number of infections, preterm birth, birth asphyxia, stillbirths, and small-for-gestational-age infants are the leading causes of perinatal mortality.

Key words: evolutionary selective pressure, great obstetric syndromes, length of gestation, obstetric dilemma
women seen with preeclampsia, particularly recurrent, severe, and early-onset preeclampsia and eclampsia, is of particular concern to us because these conditions have a high mortality and morbidity, are impossible to predict, and their pathogenesis is still somewhat mysterious.

Here we review data relating to preeclampsia in indigenous Africans and in women of African ancestry elsewhere in the world. We discuss the idea that in these women, apart from the obvious, cultural and socioeconomic factors and different priorities in health care, there are additional biological reasons why the preeclampsia syndromes are such a prominent feature of African obstetrics. Our findings also lead us to question whether there are other characteristics of pregnancy and parturition that differ in African women.

### Preeclampsia and the great obstetric syndromes

An important determinant of preeclampsia is failure of placentation, particularly the physiological transformation of spiral arteries, which leads to a stressed, underperfused placenta. Preeclampsia is one of a spectrum of pregnancy disorders that may result from this underlying pathogenesis, including fetal growth restriction (FGR), stillbirth, abruptio placenta, and some cases of preterm labor with intact membranes and prelabor rupture of membranes. Because of the overlap in these conditions, it is useful to think of them together as the great obstetric syndromes (GOS) (Appendix).

All these conditions are seen very frequently in Mulago Hospital. However, FGR cannot be reliably diagnosed without accurate knowledge of gestational age, and low birthweight may result from a variety of causes. Similarly, stillbirth is a heterogeneous condition that can result from congenital infection, birth asphyxia, or birth trauma as well as poor uteroplacental perfusion.

Because preeclampsia is a recognized clinical entity characterized by new onset of hypertension and proteinuria after 20 weeks’ gestation, we have focused on this disorder. The exact prevalence of preeclampsia in SSA is unknown because detailed clinical records of all births are lacking. Distinguishing between true preeclampsia and pregnancy-induced hypertension is also difficult because proteinuria may not be adequately measured. A further problem is a lack of information on preeclampsia underperfused placenta. Preeclampsia and the great obstetric syndromes are such a mysterious. And ethnicity or race (Tables 2 and 3). Of 4 million births recorded in the National Vital Statistics Report, pregnancy-associated hypertension was more common in AA (5.0%) and least frequent in Hispanics (2.9%).

A study of more than 2 million pregnancies in New York using data from hospital discharge records found that the rates of preeclampsia were substantially higher among AA compared with European Americans. This was even more obvious when confounders such as diabetes and maternal age were taken into account. Furthermore, the difference persisted after stratification for socioeconomic status based on area of residence.

Two other large studies in the United States, each with more than 1 million women also found that preeclampsia was more common in AA compared with European Americans. One of these studies took data from the National Inpatient Sample in which information was also available on health insurance and income level; when this was taken

| TABLE 1 | Data for the maternity unit in Mulago Hospital, Uganda |
|---------|---------------------------------------------|
| Variable | 2009 | 2010 | 2011 |
| Live births | 30,247 | 31,585 | 32,633 |
| Cesarean sections | 1260 | 1303 | 1230 |
| Ruptured uterus | 125 | 119 | 206 |
| Maternal deaths | 187 | 152 | 188 |
| Attendance at antenatal clinic | 78,157 | 76,673 | 69,129 |

Nakimuli. Pregnancy, parturition and preeclampsia in Africa. Am J Obstet Gynecol 2014.
into account, the findings remained the same.23 The other study used data from women who were all Medicaid enrollees in 14 southern states.25 AA women were women who were all Medicaid enrollees the same.24 The other study used data from into account, the

| Cohort size (total/AA) | Preeclampsia or eclampsia, OR (95% CI) | Comments | Reference |
|------------------------|----------------------------------------|----------|-----------|
| 2,571,069/450,098      | 1.67 (1.64—1.71)*                      | PE in women in New York state | 23        |
| 1,030,350/161,780      | 1.59 (1.49—1.69)                       | Adjusted for maternal characteristics and obstetric history | 24        |
| 1,472,912/420,576      | 1.30 (1.28—1.33)                       | Adjusted for maternal characteristics and obstetric history | 25        |
| 299,499/n.a.           | 1.39 (1.26—1.54)*                      | Severe PE in women without chronic hypertension | 26        |
| 206,428/19,512         | 2.12 (1.85—2.42)                       | Adjusted for maternal characteristics and obstetric history | 27        |
| 330/124                | 2.25 (0.88—5.78)                       | Eclampsia, adjusted for maternal characteristics and obstetric history | 29        |
| 4702/740               | 1.40 (1.20—1.80)                       | Adjusted for maternal characteristics and obstetric history | 30        |
| 271/38                 | 2.50 (0.97—6.40)                       | Adjusted for maternal characteristics and obstetric history | 31        |
| 4314/1998              | 1.23 (0.88—1.72)                       | Adjusted for maternal characteristics and obstetric history | 32        |
| 153/35                 | 2.27 (1.26—5.92)                       | Late postpartum PE, not adjusted | 33        |
| 2394/592               | 1.53 (1.00—2.35)                       | Adjusted for maternal characteristics, obstetric history, and biochemical factors | 34        |
| 103,860/13,748         | 1.36 (1.27—1.45)*                      | PE in women with singleton birth at first delivery | 35        |
| 2,770,871/121,017      | 1.81 (1.51—2.17)                       | Eclampsia, adjusted for maternal characteristics and obstetric history | 36        |
| 127,544/12,639         | 1.41 (1.25—1.62)                       | Adjusted for maternal characteristics, chronic hypertension excluded | 37        |
| 16,300/6000            | 1.63 (1.58—1.69)*                      | Eclampsia in racial minorities, not adjusted, not significant | 38        |
| 1355/374               | 3.20 (1.04—9.93)                       | PE in women without chronic hypertension | 39        |
| 500/68                 | 2.29 (1.16—4.53)                       | Recurrent PE, adjusted for maternal characteristics and obstetric history | 40        |
| 10,755/5555            | 1.30 (1.07—1.58)                       | Adjusted for maternal characteristics | 41        |
| 2947/156               | 1.62 (0.00—3.20)                       | No effect when analyzed by recruitment center | 42        |

Maternal characteristics generally include maternal age, body mass index, and smoking. Obstetric history generally includes parity, chronic hypertension, and diabetes.

CI, confidence interval; n.a., not available; OR, odds ratio; PE, preeclampsia.

* OR was calculated from the data.

Nakimuli. Pregnancy, parturition and preeclampsia in Africa. Am J Obstet Gynecol 2014.

Preeclampsia or eclampsia studies among African Americans

for both eclampsia and preeclampsia in nulliparous and parous women have also shown AA are at higher risk (Table 2).28-36 Confounding factors such as obesity, preexisting chronic hypertension, and diabetes are difficult to control for and are likely to contribute to the increased risk of preeclampsia among AA, particularly in the case of chronic hypertension.37-39 That preeclampsia may not be wholly explained by higher rates of chronic hypertension among AA women is suggested by a comparison between African and European Americans without chronic hypertension; the prevalence of hypertension in pregnancy was similar, but AA women still had an increased diagnosis of preeclampsia.40 Similar findings were made much earlier by the Collaborative Perinatal project, which revealed a higher incidence of preeclampsia and eclampsia among AA women compared with their European counterparts, irrespective of whether there was preexisting hypertension.41 Investigation of the GOS other than preeclampsia is more difficult because of the problems in accurate diagnosis described above. Nonetheless, a consistent message is that ethnic disparities exist for all the GOS (spontaneous preterm labor, FGR, stillbirth, and other poor obstetric outcomes), and all have an increased frequency among AA.26,42-45 In a study of more than 5 million births comparing birth outcomes between US-born and foreign-born women, women of African ancestry had the highest rates of infant mortality, low birthweight, and preterm births, whether US born or foreign.
In addition, the risk of preterm birth, stillbirth, and low birthweight is increased not only in AA women but also with AA fathers. Explanations for the disparities found between women with African or European ancestry have been poor socioeconomic status with lower incomes and level of education, lack of medical insurance, poor utilization of preconception and antenatal services, stress, discrimination, and residential segregation. Several reports have tried to determine the impact of these factors; for example, women of African ancestry were at an increased risk of preeclampsia in a second pregnancy, but this was not associated with Medicaid enrollment.

Many of the socioeconomic factors that may contribute to poor obstetric outcomes also apply to the Hispanic population in the United States, yet several studies have noted that preeclampsia, low birthweight, and stillbirth are similar or even better than for white women, the Hispanic paradox. Using information from the Duke University Birth Database, AA women had higher rates of preeclampsia (10.2%) than the European (8%) or Hispanic women (6.2%), even though the socioeconomic status of Hispanic and AA women was similar.

Preeclampsia among more recent African immigrants to other countries

Large numbers of Africans have migrated to Europe and other high-income countries, mainly in the past 50 years. Obstetric outcomes for these recent African immigrants are informative, particularly because these births often take place in countries with good records and universal health care systems (Table 3). For example, a large study of more than 100,000 women who immigrated to Ontario between 1985 and 2000 showed that the racial groups with the highest risk of severe preeclampsia were from the Caribbean or SSA.

Similar findings were made in The Netherlands where the highest risk for eclampsia and preeclampsia was from women from SSA. Cape Verdean and Antillean women were also at higher risk of preeclampsia in a report from Rotterdam, The Netherlands. A large number of Ethiopians have settled in Israel since the 1980s where prenatal and obstetric care is standardized with equal medical insurance, and in this group severe preeclampsia was more likely to occur.

**TABLE 3**

| Cohort size (total/Africans) | Preeclampsia, OR or RR (95% CI) | African origin | Comments | Location | Reference |
|-----------------------------|---------------------------------|---------------|----------|----------|-----------|
| 118,849/15,218              | 3.34 (2.25–4.96)                | Caribbean     | Adjusted for maternal characteristics | Canada   | 49        |
| 118,849/9130                | 3.14 (2.04–4.83)                | SSA           | Adjusted for maternal characteristics | Canada   | 49        |
| 2413/317                    | 2.40 (1.10–5.60)                | SSA, Surinam, Antilles | Univariate analysis | The Netherlands | 50        |
| 2506/29                     | 2.70 (1.20–6.20)                | Antilles      | Eclampsia in cases of SAMM, adjusted for maternal characteristics and obstetric history | The Netherlands | 51        |
| 2506/90                     | 6.20 (3.60–10.6)                | SSA           | Eclampsia in cases of SAMM, adjusted for maternal characteristics and obstetric history | The Netherlands | 51        |
| 6215/331                    | 2.06 (1.04–4.09)                | Cape Verde    | Adjusted for maternal characteristics and obstetric history | The Netherlands | 52        |
| 6215/264                    | 1.87 (0.86–4.06)                | Antilles      | Adjusted for maternal characteristics and obstetric history | The Netherlands | 52        |
| 1728/576                    | 2.47 (1.02–6.00)                | Ethiopia      | Standardized care between the groups compared | Israel   | 53        |
| 76,158/11,395               | 2.60 (2.32–2.92)                | Caribbean     | Adjusted for maternal characteristics and obstetric history | United Kingdom | 54        |
| 8366/1581                   | 3.64 (1.84–7.21)                | n.a.          | Adjusted for maternal characteristics and obstetric history | United Kingdom | 55        |
| 15,639/356                  | 0.90 (0.53–1.51)                | SSA           | No increased risk | Sweden   | 56        |
| 165,001/986                 | n.a.                            | African, Somalia | No increased risk | Finland   | 58        |
| 526/158                     | 3.90 (1.70–8.94)                | SSA           | Early-onset PE compared to late onset (<28 or <34 weeks) | France   | 68        |

Maternal characteristics generally include maternal age, body mass index, and socioeconomic status. Obstetric history generally includes parity, chronic hypertension, and diabetes.

CI, confidence interval; n.a., not available; OR, odds ratio; PE, preeclampsia; RR, relative risk; SAMM, severe acute maternal morbidity.

a OR was calculated from the data.

Nakimuli. Pregnancy, parturition and preeclampsia in Africa. Am J Obstet Gynecol 2014.
Large groups of women of African ancestry live in London where access to National Health Service hospitals is freely available and home deliveries are rare. In a survey of 80,000 pregnancies that included women of European and Asian ancestry, 15% had African ancestry, and this was the second strongest risk factor for preeclampsia after chronic hypertension and also carried a higher risk of other poor obstetric outcomes such as FGR and stillbirth. Similarly, African ancestry was a risk factor for early-onset preeclampsia compared with all other racial groups, and this remained so, even after adjusting for age, body mass index, and other maternal characteristics. These and other studies of African immigrants also highlight the increased risk of GOS such as stillbirths and FGR similar to AA.

Severity and recurrence of preeclampsia

The early onset and severity of preeclampsia in women from Uganda is also a cause of concern, although the latter may reflect the late admittance to Mulago Hospital. In a US national hospital discharge survey, higher mortality from preeclampsia and eclampsia was reported among women of African ancestry compared with European Americans, but only one-third or less of the difference could actually be attributed to the higher prevalence. Pregnancy-related deaths from preeclampsia/eclampsia were 3 times higher in AA women compared with Europeans.

In the UK Maternal Death Review for the period 2006-2008, 22 deaths occurred as a result of preeclampsia and eclampsia. Despite being a minority group, 6 of these deaths were Africans and the authors noted: “Black African women seem particularly susceptible to aggressive forms of preeclampsia. To establish if this is true, and what might be the underlying genetic or other pathophysiological mechanisms, further research is required.”

After a woman has had preeclampsia in her first pregnancy, the risk of recurrence is increased, with a relative risk of 15.0 cited in an authoritative Norwegian study of more than 2 million women. Increased risk of other GOS, even if preeclampsia does not occur, is also clear from another large study in Sweden, and other reports support this conclusion.

Large studies of this kind are still not available for African women resident in SSA, but our own experience in Kampala is that recurrent preeclampsia does occur frequently. In London, 23% of 500 women with previous preeclampsia had recurrent disease that required delivery before 37 weeks, and African compared with European ancestry was a significant predictor. It also seems that when preeclampsia does occur in the second pregnancy in AA women, it is severe, early-onset disease with associated FGR and preterm birth. A recent study from France suggests that women of African ancestry are more at risk for early-onset preeclampsia and more likely to have had a previous history of preeclampsia compared with other groups, including women from North Africa, despite the even higher incidence of chronic hypertension in the latter group.

Summary

Our comprehensive review of the literature identified very few papers that run counter to our conclusion that women of African ancestry are at increased risk of developing preeclampsia. First, 3 studies showed that these women were not at increased risk of preeclampsia, but they had low power to detect any effect. Second, the apparent increased susceptibility to preeclampsia among AA has been dismissed as a problem of incorrect diagnosis. Third, race was discounted as a significant risk factor for preeclampsia in another study, but data regarding AA women were combined with that for other minority races so that the analysis could not provide a meaningful comparison.

Genetics of preeclampsia

That there is a genetic component to preeclampsia has long been suspected. Daughters of women with preeclampsia have more than twice the risk of developing the disease themselves, and sisters of affected women, even if not born from a preeclamptic pregnancy, are also at increased risk. These findings of familial aggregation in preeclampsia are also true for the other GOS. Although environmental factors, particularly influences acting in utero, are important, some of the risk is likely to be genetic. Indeed, a study of female twin pairs with known zygosity estimated that the heritability of preeclampsia was approximately 54%. Could there be particular susceptibility genes associated with the higher frequency of preeclampsia in women of African ancestry? A case-control study of preeclampsia in Latinas, a group with admixture from European, African, and native Americans, did show, using ancestry informative markers, that African ancestry was associated with preeclampsia.

The role of the fetal (father’s) genes is less obvious, but many reports indicate a paternal contribution to the risk. Intergenerational and familial aggregation also point to genetic factors derived from both maternal and fetal genes, with most risk coming from maternal genes that may act either in the mother or her fetus. A drive to look for the susceptibility genes for preeclampsia has so far been disappointing. The studies generally have small numbers of subjects and have not been replicated.

Genome-wide association screening is an unbiased approach to look for susceptibility genes in complex disorders and has been used in preeclamptic cohorts, but, although various single-nucleotide polymorphism candidates have been identified, the lack of statistical power is again a problem. Systematic meta-analyses of these studies found 7 single-nucleotide polymorphisms significantly associated near genes involved in processes such as coagulation, the renin-angiotensin system, and inflammation.

This highlights an important issue: searching for variants associated with preeclampsia only in the maternal genome will reveal genes mainly associated with the tertiary systemic syndrome and not those maternal and/or fetal genes involved in physiological transformation of the arteries or to the subsequent stress response of the placenta to the reduced blood flow. The clear increased risk of
cardiovascular disease in women who have had preeclampsia again points to a separate set of susceptibility genes that are acting systemically and not during early placentation.94,95

We have taken a different approach and focused on the primary defect of poor placentation. This is based on the idea that regulation of trophoblast behavior during placentation is mediated by allogeneic recognition of trophoblast major histocompatibility complex molecules by maternal lymphocytes.96 The findings that specialized immune cells, uterine natural killer (NK) cells, accumulate at the site of placentation, together with the discovery of NK receptors, the killer-cell immunoglobulin-like receptor family (KIR) and their cognate HLA-C trophoblast ligands have demonstrated how the mother can discern the presence of a genetically different individual.97-99

KIR and HLA are the most polymorphic gene families in humans, and we have shown that particular maternal KIR in combination with fetal HLA-C variants are associated with preeclampsia and the other GOS.100-102 Women who have 2 KIR A haplotypes (KIR AA genotype) are at risk when there is a HLA-C allele belonging to the C2 group in the fetus. Furthermore, the origin of the fetal HLA-C2 is important; the most risk is from a C2 allele inherited from the father.

We are now undertaking a similar study at Mulago Hospital, and preliminary findings illustrate the same maternal KIR/fetal HLA-C combinations associated with preeclampsia in African women. Interestingly, the frequency of the fetal HLA-C2 variant that confers risk is increased in Ugandans compared with Europeans and Asians.103 Furthermore, there is enormous variability of KIR genes in Africans with far more genotypes and more allelic variation at individual KIR loci.104

How these genetic findings translate into the function of uterine NK cells is a challenge, given the ethical and logistical difficulties in experimenting with these cells. Functionally, we would predict that the risky combination results in very strong inhibition of uterine NK cells (Figure 1). Triggering of uterine NK cells by HLA-C2 target cells in vitro from women who have a protective KIR B haplotype (in which the activating KIR for HLA-C2, KIR2DS1, is located) results in secretion of cytokines and chemokines that may facilitate trophoblast invasion and vascular transformation.105 Thus, we propose that the uterine immune system using highly variable maternal KIR/fetal HLA-C interactions subtly defines the boundary between mother and baby, limiting the highly invasive placenta while at the same time ensuring the fetus receives sufficient nourishment for normal development through remodeling of the spiral arteries.

The obstetric dilemma

Overall, the data we have brought together in this review suggest that preeclampsia and other GOS occur more commonly in women of African ancestry compared with other ethnic groups, and this is not wholly accounted for by confounding social, cultural, and medical

FIGURE 1
Maternal KIR/fetal HLA-C interactions at the site of placentation

In these 2 scenarios, the mother is HLA-C1 homozygous and the fetus has inherited an HLA-C2 group allele from the father. If the mother has a KIR AA genotype that lacks activating KIR and has a strong inhibitory KIR for HLA-C2 (KIR2DL1), poor placentation results. In contrast, if the mother has a KIR AB or BB genotype containing the activating KIR for HLA-C2 (KIR2DS1), uterine natural killer cells are triggered to produce increased amount of cytokines and chemokines (eg, granulocyte-macrophage colony—stimulating factor) that enhance placentation.

Nakimuli. Pregnancy, parturition and preeclampsia in Africa. Am J Obstet Gynecol 2014.
influences. It also seems that the risk of preeclampsia in African immigrants to Europe is increased irrespective of their area of origin in Africa, apart from North Africans. All these observations point to a need to investigate possible biological/genetic reasons contributing to the higher risk of preeclampsia in SSA.

We would anticipate that there would be strong selective pressure against a disorder that, without medical intervention, is frequently fatal to mother and child and occurs in 5-10% of first pregnancies. A failure of the physiological transformation of uterine arteries is a common feature of all the GOS, and this results in a reduced placental supply of oxygen and nutrients, lower birthweights, and the risk of preterm labor and superimposed preeclampsia. However, at the same time, we have to consider that maternal and neonatal mortality is not only high under circumstances of reduced fetal nutrition but also when babies are too large for the pelvis.

Compared with other primates, the passage of the large human fetal head through a bony pelvis is a tight fit, requiring rotation of the head as it goes through the birth canal as a consequence of adaptation to bipedalism. The high maternal and neonatal mortality associated with extremes of birthweight, sometimes called the obstetric dilemma, has been described as “perhaps the most clear-cut example of a human character subject to stabilizing selection” (Figure 2).

The optimal survival of babies weighing between 6 and 8 lb (2.5-3.5 kg) seems to be a universal feature of human populations. If babies become too large, the risk of obstructed labor is increased. As in the rest of SSA, at Mulago Hospital we not only have many disordered pregnancies arising from failure of placentation, but we also experience frequent births with prolonged obstructed labor because of cephalopelvic disproportion. Without cesarean section, this leads to birth asphyxia, postpartum hemorrhage, pelvic trauma, sepsis, and long-term problems such as vesicovaginal fistula. In Uganda, 2% of all women have had an obstetric fistula. Therefore, the higher cesarean section rates in high-income countries in women of African ancestry may reflect not just delivery of women with preeclampsia but also an increased frequency of obstructed labor.

A detailed audit from the Royal College of Obstetricians and Gynaecologists in the United Kingdom highlighted the higher cesarean section rates in women of African ancestry, even when confounders such as age, parity, birthweight, and presentation were considered. Furthermore, shoulder dystocia has also been reported to occur more commonly in AA women.

These findings may in part be accounted for by measurements of the bony pelvis revealing that there is even less room for the fetal head in women of African ancestry. Although pelvimetry may not be a useful indicator in predicting cephalopelvic disproportion in individual patients, the measurements made of the pelvis, notably the pelvic inlet, outlet, length of sacrum, and pelvic floor area, are all smaller in women of African ancestry compared with those of European ancestry.

A possible consequence is that the fetal head engages into the pelvis late, only when labor commences, whereas this occurs in the last month of gestation in European and Asian women. Several reports also document the fact that normal term in African pregnancy occurs at only approximately 38 weeks’ gestation, which is 2 weeks earlier than in non-Africans, possibly facilitating birth before the baby becomes too big. If births are occurring earlier, it would certainly then be advantageous for the fetus to mature more quickly, and indeed, African babies frequently pass meconium with no sign of fetal distress. There is also accelerated lung maturity. Thus, the difficulties imposed by the birth process and the passage of the head and shoulders through the bony pelvis seem to have driven biological changes in many aspects of pregnancy.
This clear trade-off between the size of the pelvis and head room will benefit babies who have intermediate birthweights, and the 2 extremes with reduced survival will be selected against. Of interest will be a study of maternal KIR/fetal HLA-C variants in pregnancies with obstructed labor as the KIR A and B haplotypes and HLA-C1 and C2 groups are under stabilizing selection and are found at different frequencies across the world’s populations.

Therefore, when considering why preeclampsia persists in populations, it is important not only to consider the GOS but also the morbidity and mortality at the other end of the birth weight distribution. It may be that the consequences of these contrasting selective pressures not only affect higher birthweight babies but also the tendency for enhanced numbers of undernourished babies with the concomitant maternal syndrome of preeclampsia. That is to say that selection in a population for reduced fetal size may lead to the persistence of factors predisposing to preeclampsia.

Future directions

There is an urgent need to document obstetric events better in SSA, and the lack of detailed electronic hospital records in the hospitals as well as the failure to record all births in the population is a major difficulty for any maternal health research program. For example, proper assessment of gestational age at delivery will be crucial in the accurate diagnosis of the GOS. The record systems documenting obstetric and neonatal problems are still inadequate throughout SSA, and this is clearly a major priority. Introduction of record systems in Zambia had an immediate impact on the shorter gestational age and describing Zambia had an immediate impact on the morbidity and mortality at the other end of the birth weight distribution. It may be that the consequences of these contrasting selective pressures not only affect higher birthweight babies but also the tendency for enhanced numbers of undernourished babies with the concomitant maternal syndrome of preeclampsia. That is to say that selection in a population for reduced fetal size may lead to the persistence of factors predisposing to preeclampsia.

ACKNOWLEDGMENTS

We thank all the clinical and research staff of the Mulago Hospital and the patients and their families who made this work possible. We are also grateful to Graham Burton, Hillary Critchley, David Dunne, and Christopher Redman for their helpful comments on the draft manuscript.

REFERENCES

1. World Health Organization. Trends in maternal mortality: 1990 to 2008. Geneva (Switzerland): World Health Organization; 2010.
2. World Health Organization. The World Health Report 2005. Make every mother and child count. Geneva (Switzerland): World Health Organization; 2005.
3. World Health Organization. Reduction of maternal mortality: a joint WHO/UNIFPA/UNICEF/World Bank statement. Geneva (Switzerland): World Health Organization; 1999.
4. Khan KS, Wojdyla D, Say L, Gømezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet 2006;367:1066-74.
5. Lawn JE, Cousens S, Zupan J. Four million neonatal deaths: when? where? why? Lancet 2005;365:891-900.
6. Uganda Bureau of Statistics (UBOS) and ICF International Inc.Uganda Demographic and Health Survey 2011, Kampala, Uganda. Kampala (Uganda): Ganda Bureau of Statistics (UBOS) and ICF International Inc; 2012.
7. Kaye D, Mirembe F, Aziga F, Namukema B. Maternal mortality and associated near-misses among emergency intrapartum obstetric referrals in Mulago Hospital, Kampala, Uganda. East Afr Med J 2003;80:144-9.
8. Wandabwa JN, Doyle P, Longo-Mbenza B, et al. Human immunodeficiency virus and AIDS and other important predictors of maternal mortality in Mulago Hospital Complex Kampala Uganda. BMC Public Health 2011;11:565.
9. Redman CWG, Sargent IL. Immunological factors and placentation: implications for pre-eclampsia. In: Lyall F, Belfort M, eds. Pre-eclampsia. Cambridge (United Kingdom): Cambridge University Press; 2007.
10. Redman CW, Sargent IL. Latest advances in understanding pre-eclampsia. Science 2005;308:1592-4.
11. Ananth CV, Vintzileos AM. Ischemic placental disease: epidemiology, risk factors. Eur J Obstet Gynecol Reprod Biol 2011;159:77-82.
12. Khong TY, De Wolf F, Robertson WB, Brossons I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986;93:1049-59.
13. Brossons I, Pinjenborg R, Vercruysse L, Romero R. The “Great Obstetrical Syndromes” are associated with disorders of deep placentation. Am J Obstet Gynecol 2011;204:193-201.
14. Romero R, Kusanovic JP, Kim CJ. Placental bed disorders in the genesis of the great obstetrical syndromes. In: Brossons I, Pinjenborg R, Romero R, eds. Placental bed disorders: basic science and its translation to obstetrics. Cambridge, NY: Cambridge University Press; 2010:271-89.
15. Smith GC. First-trimester determination of complications of late pregnancy. JAMA 2010;303:561-2.
16. North R. Classification and diagnosis of pre-eclampsia. In: Lyall F, Belfort M, eds. Pre-eclampsia. Cambridge (United Kingdom): Cambridge University Press; 2007.
17. Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Gilstrap L, Wenstrom KD. Hypertensive disorders in pregnancy. Williams obstetrics. New York: McGraw Hill; 2005.
18. Reed TE. Caucasian genes in American Negroes. Science 1969;165:762-8.
19. Chakraborty R, Kambhoi MI, Ferrell RE. “Unique” alleles in admixed population: a strategy for determining “hereditary” population differences of disease frequencies. Ethn Dis 1991;1:246-56.
20. Dekker GA. Risk factors for preeclampsia. Clin Obstet Gynecol 1999;42:422-35.
21. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 2001;357: 53-6.
22. Martin JA, Hamilton BE, Ventura SJ, et al. Births: final data for 2009. Natl Vital Stat Rep 2011;60:1-70.
23. Tanaka M, Jaamaa G, Kaiser M, et al. Racial disparity in hypertensive disorders of pregnancy in a New York State: a 10-year longitudinal population-based study. Am J Pub Health 2007;97:163-70.
24. Shen JJ, Tymkow C, MacMullen N. Disparities in maternal outcomes among four ethnic populations. Ethn Dis 2005;15:492-7.
25. Zhang S, Cardarelli K, Shim R, Ye J, Booker KL, Rust G. Racial disparities in economic and clinical outcomes of pregnancy among Medicaid recipients. Matern Child Health J 2013;17:1518-25.
26. Zwart JJ, Jonkers MD, Richters A, et al. Ethnic disparity in severe acute maternal morbidity associated with hypertensive disorders in pregnancy in the United States. Hypertens Pregnancy 2005;24:281-90.
27. Cabacungan ET, Ngui EM, McGinley EL. Maternal morbidity associated with hypertensive complications in Wisconsin. Matern Child Health J 2014;18:82-9.
28. Saftlas AF, Olson DR, Franks AL, Atrash HK, Pokras R. Epidemiology of preeclampsia and eclampsia in the United States, 1979-1986. Am J Obstet Gynecol 1990;163:460-5.
29. Saamadi AR, Mayberry RM, Zaidi AA, Pleasant JC, McShie N Jr, Rice RJ. Maternal hypertension and associated pregnancy complications among African-American and other women in the United States. Obstet Gynecol 1998;87:557-63.
30. Bryant AS, Seely EW, Cohen A, Lieberman E. Patterns of pregnancy-related hypertension in black and white women. Hypertens Pregnancy 2005;24:281-90.
31. Niswander KR, Gordon M. The women and their pregnancies: the collaborative perinatal study of the National Institute of Neurological Diseases and Stroke. Philadelphia, PA: W. B. Saunders Co; 1972.
32. MacDorman MF. Race and ethnic disparities in fetal mortality, perterm birth, and infant mortality in the United States: an overview. Semin Perinatol 2011;35:200-8.
33. Bryant AS, Worjoloh A, Caughey AB, Washington AE. Racial/ethnic disparities in obstetric outcomes and care: prevalence and determinants. Am J Obstet Gynecol 2010;202: 335-43.
34. Brown HL, Chireau MV, Jaillah Y, Howard D. The "Hispanic paradox": an investigation of racial disparity in pregnancy outcomes at a tertiary care medical center. Am J Obstet Gynecol 2007;197:197.e1-7; discussion 97.e7-9.
35. Mbah AK, Alio AP, Marty PJ, Bruder K, Wilson R, Salihu HM. Recurrent versus isolated pre-eclampsia and risk of feto-infant morbidity outcomes: racial/ethnic disparity. Eur J Obstet Gynecol Reprod Biol 2011;156:23-8.
36. Singh GK, Yu SM. Adverse pregnancy outcomes: differences between US- and foreign-born women in major US racial and ethnic groups. Am J Public Health 1996;86:837-43.
37. Palomar L, DeFranco EA, Lee KA, Adzworth JE, Muglia LJ. Paternal race is a risk factor for preterm birth. Am J Obstet Gynecol 2007;197:152.e1-7.
38. Sriivasjois RM, Shah S, Shah PS. Biracial couples and adverse birth outcomes: a systematic review and meta-analyses. Acta Obstet Gynecol Scand 2012;91:1134-46.
39. Urquilla ML, Ying I, Glazier RH, Berger H, De Souza LR, Ray JG. Serious pre eclampsia among different immigrant groups. J Obstet Gynaecol Can 2012;34:348-52.
40. Knuist M, Bonsel GJ, Zondervan HA, Treffers PE. Risk factors for preeclampsia in nulliparous women in distinct ethnic groups: a prospective cohort study. Obstet Gynecol 1998;92:174-8.
41. Zwart JJ, Jonkers MD, Richters A, et al. Ethnic disparity in severe acute maternal morbidity: a nationwide cohort study in The Netherlands. Eur J Pub Health 2011;21: 229-34.
42. Bouthoorn SH, Gaillard R, Steegers EA, et al. Ethnic differences in blood pressure and hypertensive complications during pregnancy: the Generation R study. Hypertension 2012;60: 198-205.
43. Salim R, Mfar A, Garmi G, Shalev E. Comparison of intrapartum outcome among immigrant women from Ethiopia and the general obstetric population in Israel. Int J Gynaecol Obstet 2012;118:161-5.
44. Kshai AA, Rezende J, Akolekar R, Syngelaki A, Nicolaides KH. Maternal racial origin and adverse pregnancy outcome: a cohort study. Ultrasound Obstet Gynecol 2013;41:278-85.
45. Poon LC, Kametas NA, Chelemen T, Leal A, Nicolaides KH. Maternal risk factors for hypertensive disorders in pregnancy: a multi-variate approach. J Hum Hypertens 2010;24: 104-10.
46. Essen B, Hanson BS, Ostergren PO, Lindquist PG, Gudmundsson S. Increased perinatal mortality among sub-Saharan immigrants in a city-population in Sweden. Acta Obstet Gynecol Scand 2000;79:737-43.
47. Jenum AK, Sommer C, Sletner L, Morkrid K, Biaerug A, Mosdal A. Adiposity and hyperglycaemia in pregnancy and related health outcomes in European ethnic minorities of Asian and African origin: a review. Food Nutr Res 2013;57.
48. Malin M, Gissler M. Maternal care and birth outcomes among ethnic minority women in Finland. BMC Public Health 2009;9:84.
49. Tucker MJ, Berg CJ, Callaghan WM, Hsia J. The black-white disparity in pregnancy-related mortality from 5 conditions: differences in prevalence and case-fatality rates. Am J Public Health 2007;97:247-51.
50. Mackay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from pre eclampsia and eclampsia. Obstet Gynecol 2001;97:533-8.
51. Cantwell R, Clutton-Brock T, Cooper G, et al. Saving mothers’ lives: reviewing maternal deaths to make motherhood safer: 2000-2008. The Eighth Report of the Confidential Enquiries Into Maternal Deaths in the United Kingdom. BJOG 2011;118(Suppl 1):1-203.
52. Klungsøyr K, Marken NH, Irgens L, Vollen SE, Skjaerven R. Secular trends in the epidemiology of pre-eclampsia throughout 40 years in Norway: prevalence, risk factors and perinatal survival. Paediatr Perinat Epidemiol 2012;26:190-8.
53. Hjartardottir S, Leifsson BG, Geirsson RT, Leifsson BG, Geirsson RT. Ethnic differences in blood pressure and hypertensive disorders in pregnancy: a population-based study. Am J Obstet Gynecol 2013;209:229.e1-7.
66. Ananth CV, Pelletier MR, Chavez MR, Kirby RS, Getahun D, Vintzileos AM. Recurrence of ischemic placental disease. Obstet Gynecol 2007;110:128-33.
67. Bramham K, Birley AL, Seed P, Poston L, Shennan AH, Chappell LC. Adverse maternal and perinatal outcomes in women with previous preeclampsia: a prospective study. Am J Obstet Gynecol 2011;204:512-9.
68. Anselm O, Girard G, Stepanian A, Azria E, Montaloi L. Influence of ethnicity on the clinical and biologic expression of pre-eclampsia in the ECLAXIR study. Int J Gynaecol Obstet 2011;115:153-6.
69. Sbali BM, Gordon T, Thor E, et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol 1995;172:642-8.
70. Chesley LC, Cooper DW. Genetics of hyperteny in pregnancy: possible single gene control of pre-eclampsia and eclampsia in the descendants of eclamptic women. Br J Obstet Gynaecol 1986;93:898-908.
71. Arrgmimsson R, Bjornsson S, Geirsson RT, Bjornsson H, Walker JK, Snaedal G. Genetic and familial predisposition to eclampsia and pre-eclampsia in a defined population. Br J Obstet Gynaecol 1990;97:762-9.
72. van Dijk M, Oudejans C. (Epi)genetics of pre-eclampsia in the 21st century: relationships to fetal and maternal genetic components in a population based cohort. BMJ 2005;331:877.
73. Mogren I, Hogberg U, Winkvist A, Stenlund H. Familial occurrence of preeclampsia. Epidemiology 1999;10:518-22.
74. Skjaerven R, Vatten LJ, Wilcox AJ, Ronning T, Irgens LM, Lie RT. Recurrence of pre-eclampsia across generations: exploring fetal and maternal genetic components in a population based cohort. BMJ 2005;331:877.
75. Carr DB, Epplen J, Johnson CO, Easterling TR, Critchlow CW. A sister’s risk: family history as a predictor of preeclampsia. Am J Obstet Gynecol 2005;193:965-72.
76. Dawson LM, Parfrey PS, Hefferton D, et al. Familial risk of preeclampsia in Newfoundland: a population-based study. J Am Soc Nephrol 2002;13:1901-6.
77. Nilsson E, Salonen Ros H, Cnattingius S, Lichtenstein P. The importance of genetic and environmental effects for pre-eclampsia and gestational hypertension: a family study. BJOG 2004;111:200-6.
78. Plunkett J, Borecki I, Morgan T, Stamilo D, Muglia LJ. Population-based estimate of sibling risk for preterm birth, preterm premature rupture of membranes, placental abruption and pre-eclampsia. BMC Genet 2008;9:44.
79. Toivonen S, Keski-Nisula L, Saarikoski S, Heinonen S. Risk of placental abruption in first-degree relatives of index patients. Clin Genet 2004;66:244-6.
80. Porter TF, Fraser AM, Hunter CY, Ward RH, Vanner MW. The risk of preterm birth across generations. Obstet Gynecol 1997;90:63-7.
81. Winkvist A, Mogren I, Hogberg U. Familial patterns in birth characteristics: impact on individual and population risks. Int J Epidemiol 1998;27:248-54.
82. Salonen Ros H, Lichtenstein P, Lipworth L, Cnattingius S. Genetic effects on the liability of developing pre-eclampsia and gestational hypertension. Am J Med Genet 2000;91:256-60.
83. Shahabi A, Wilson ML, Lewinger JP, Goodwin TM, Stern MC, Ingles SA. Genetic admixture and risk of hypertensive disorders of pregnancy among Latinas in Los Angeles County. Epidemiology 2013;24:285-94.
84. Esplin MS, Faussett MB, Fraser A, et al. Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med 2001;344:867-72.
85. Lie RT, Rasmussen S, Brunborg H, Gjesing HK, Lie-Nielsen E, Irgens LM. Fetal and maternal contributions to risk of pre-eclampsia: population based study. BMJ 1998;316:1343-7.
86. Robillard PY, Dekker GA, Hulsey TC. Revisiting the epidemiological standard of preeclampsia: primigravidae or primipaternity? Eur J Obstet Gynecol Reprod Biol 1999;84:37-41.
87. Li DK, Wi S. Changing paternity and the risk of preeclampsia. Reproductive Sci 2008;15:157-62.
88. Cincotta RB, Brennecke SP. Family history of pre-eclampsia as a predictor for pre-eclampsia in primigravidae. Int J Gynaecol Obstet 1998;60:23-7.
89. ChapPELL S, Morgan L, Sareet Singh for the causes to the cures of pre-eclampsia. Clin Sci (Lond) 2006;110:443-58.
90. Zhao L, Bracken MB, DeWan AT. Genome-wide association study of pre-eclampsia detects novel maternal single nucleotide polymorphisms and copy-number variants in subsets of the hyperglycemia and Adverse Pregnancy Outcome (HAPO) study cohort. Ann Hum Genet 2013;77:277-87.
91. Buurma AJ, Turner RJ, Driessen JH, et al. Genetic variants in pre-eclampsia: a meta-analysis. Hum Reprod Update 2013;19:289-303.
92. Staines-Urias E, Paez MC, Doyle P, et al. Candidate-gene association study of mothers with pre-eclampsia, and their infants, analyzing 775 SNPs in 190 genes. Hum Hered 2007;63:1-16.
93. Gogate K. Co-evolution of human leukocyte antigen (HLA) class I ligands with killer-cell immunoglobulin-like receptors (KIR) in a genetically diverse population of sub-Saharan Africans. PLoS Genet 2013;9:e1003938.
94. Xiong S, Sharkey AM, Kennedy PR, et al. Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2. J Clin Invest 2010;120:4102-10.
95. Naikmul A, Chazara O, Farrell L, et al. Killer cell immunoglobulin-like receptor (KIR) genes and their HLA-C ligands in an Ugandan population. Immunogenetics 2013;65:765-75.
96. Norman PJ, Hollenbach JA, Nemat-Gorgani N, et al. Co-evolution of human leukocyte antigen (HLA) class I ligands with killer-cell immunoglobulin-like receptors (KIR) in a genetically diverse population of sub-Saharan Africans. PLoS Genet 2013;9:1199-206.
97. Aitbiol MM, Chersevani F, Ledger W. Birth and human evolution: anatomical and obstetrical mechanics in primates. Westport Bergin and Garvey; 1996.
98. Cavalli-Sforza LL, Bodmer WF. The genetics of human populations. San Francisco: W. H. Freeman and Company; 1971:612-3.
99. Wittman AB, Wall LL. The evolutionary origins of obstructed labor: bipolarity, encapulization, and the human obstetric dilemma. Obstet Gynecol Surv 2007;62:739-48.
100. Thomas J, Paranjothy S. Royal College of Obstetricians and Gynaecologists Clinical Effectiveness Support Unit. National Sentinel Caesarean Section Audit Report. London, UK: RCOG Press; 2001.
101. Cheng YW, Norwitz ER, Caughey AB. The relationship of fetal position and ethnicity with shoulder dystocia and birth injury. Am J Obstet Gynecol 2006;195:856-62.
102. Pattinson R. Pelvimetry for fetal cephalic presentations at term. Cochrane Database Syst Rev 2000:CD000161.
113. Handa VL, Lockhart ME, Fielding JR, et al. Racial differences in pelvic anatomy by magnetic resonance imaging. Obstet Gynecol 2008;111:914-20.

114. Baragi RV, Delancey JO, Caspari R, Howard DH, Ashton-Miller JA. Differences in pelvic floor area between African American and European American women. Am J Obstet Gynecol 2002;187:111-5.

115. Patruquim ML, Steyn M, Loth SR. Metric analysis of sex differences in South African black and white pelvis. Forensic Sci Int 2005;147:119-27.

116. Steer PJ. The mechanisms and management of normal labour. In: Chamberlain G, Steer P, eds. Turnbull’s obstetrics. London: Churchill Livingstone; 2001.

117. Omigbodun AO, Adewuyi A. Duration of human singleton pregnancies in Ibadan, Nigeria. J Natl Med Assoc 1997;89:617-21.

118. Loftin R, Chen A, Evans A, Defranco E. Racial differences in gestational age-specific neonatal morbidity: further evidence for different gestational lengths. Am J Obstet Gynecol 2012;206:259.e1-6.

119. Patel RR, Steer P, Doyle P, Little MP, Elliott P. Does gestation vary by ethnic group? A London-based study of over 122,000 pregnancies with spontaneous onset of labour. Int J Epidemiol 2004;33:107-13.

120. Balchin I, Whittaker JC, Lamont PF, Steer PJ. Timing of planned cesarean delivery by racial group. Obstet Gynecol 2008;111:659-66.

121. Alexander GR, Hulsey TC, Robillard PY, De Caunes F, Papiernik E. Determinants of meconium-stained amniotic fluid in term pregnancies. J Perinatol 1994;14:259-63.

122. Berman S, Tanasijevic MJ, Alvarez JG, Ludmir J, Lieberman E, Richardson DK. Racial differences in the predictive value of the TDx fetal lung maturity assay. Am J Obstet Gynecol 1996;175:73-7.

123. Floros J, Fan R, Diangelo S, Guo X, Wert J, Luo J. Surfactant protein (SP) B associations and interactions with SP-A in white and black subjects with respiratory distress syndrome. Pediatr Int 2001;43:567-76.

124. Parham P, Moffett A. Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat Rev Immunol 2013;13:133-44.

125. Chi BH, Vwalika B, Killam WP, et al. Implementation of the Zambia electronic perinatal record system for comprehensive prenatal and delivery care. Int J Gynaecol Obstet 2011;113:131-6.

126. Kaplan M. Genomics in Africa: avoiding past pitfalls. Cell 2011;147:11-3.
Appendix

Glossary

Genetic admixture: phenomenon of interbreeding between members of 2 or more different populations resulting in the exchange of genes.

Genome-wide association: a search for common genetic variants associated with a disease. Generally, the association of particular single-nucleotide polymorphism (SNPs), variation in the DNA sequence of a single nucleotide, is analyzed in individuals with the disease compared with normal matched control subjects.

Great obstetrical syndromes: major pregnancy complications such as spontaneous abortion, fetal death, abruptio placentae, fetal growth failure, preeclampsia, preterm labor, and premature rupture of membranes. These disorders all share the primary defect of failure of physiological transformation of uterine spiral arteries, but there are multiple fetal and maternal factors that determine the exact clinical outcome.

HLA-C: polymorphic classical HLA class I molecules present at the surface of most nucleated cells and also expressed by invasive trophoblast cells at the site of placentation. HLA-C molecules are important ligands for KIR receptors.

Killer cell immunoglobulin-like receptors (KIR): a family of closely related genes located in the leukocyte receptor complex on chromosome 19. KIR proteins are expressed on the surface of NK cells. KIR can have an activating or inhibitory effect on NK cell function. In all populations, 2 types of KIR haplotypes are found; KIR A haplotypes contain mainly inhibitory KIR, whereas KIR B haplotypes contain extra, mainly activating, KIR.

Linkage disequilibrium: differences in a population between the observed occurrence of some combinations of alleles or genetic markers and their expected frequencies under the assumption of independence. Linkage disequilibrium is expected to be the greatest for 2 genes located closely together on a chromosome.

NK cells: large granular lymphocytes of the innate immune system that play important roles in defense against viral infections and tumors. A specialized subset of NK cells amass at the site of placentation early in gestation.

Positive selection: type of natural selection that results in the increase of the frequency of the advantageous alleles over time.

Stabilizing selection: selection favoring intermediate values of a character over the extremes.